On January 17, 2020 ENB Therapeutics reported that it receives IND approval from the FDA for our Phase 1/2 trial evaluating the safety and efficacy of lead product ENB-003 in combination with pembrolizumab (Press release, ENB Therapeutics, JAN 17, 2020, View Source [SID1234634057]). This is a major milestone for ENB and allows our clinical trial to be initiated as planned later this year.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!